Newsletter | January 9, 2020

01.09.20 -- Cell & Gene Best Of December

 

Hello Cell & Gene readers,

 

I’m happy to bring you December’s most-clicked articles. Enjoy.

 

Erin Harris, editor in chief
Follow me on Twitter

December's Best Featured Editorial
The Journey To Get An Ovarian Cancer T-Cell Therapy Into Clinical Trials
By Kevin Honeycutt and Erin Graham, Alliance for Cancer Gene Therapy (ACGT)

Daniel J. Powell Jr., Ph.D., and his research team at the University of Pennsylvania has launched a new clinical trial to treat ovarian cancer with a pioneering therapy involving genetically modified T-cells. The trial, which has treated its first patient, almost didn’t happen.

Challenges, Short-Term Outlook Facing the Cell and Gene Sector’s Regulatory Landscape
By Erin Harris, Editor-In-Chief, Cell & Gene

Here are the critical action items cell and gene therapy professionals should heed to keep pace with the sector’s ever-evolving regulations.

CAR T-Cell Therapies: Current Limitations & Future Opportunities
By Anamika Ghosh, Ph.D., and Dana Gheorghe, Ph.D., DRG Oncology

Novel technologies to address areas left unaddressed by Kymriah and Yescarta have started streaming into the research arena. This article focuses on the barriers to widespread commercial adoption of the currently available CAR T cell therapies, and opportunities for developers of next-generation treatments.

December's Best Industry Insights
Designing The Cell Therapy Facility Of The Future
By Herman Bozenhardt, Bozenhardt Consulting Services, and Erich Bozenhardt, IPS-Integrated Project Services

In 1931, Swiss doctor Paul Niehans injected a preparation of live cells from a parathyroid gland into a dying patient. The patient subsequently recovered, and Dr. Niehans had a eureka moment — that injections of living cells can have tremendous therapeutic value.

Cell Therapy And Gene Therapy: A Case Study On Scaling Up For Commercial Manufacturing
By Werum IT Solutions America, Inc.

There are two new players on the biologics industry block – cell therapy and gene therapy. Join our featured speaker for a discussion of how cell and gene therapies differ from pharmaceuticals and learn about the challenges to achieving commercial manufacturing.

How To Scale-Up Lentiviral Vector Production Part 2: Considerations For Downstream Processing (DSP)
By CCRM

In Part 1 of our series on lentiviral vector (LVV) manufacturing we covered scale-up of upstream processing steps. Here we break down DSP into unit operations and understand how process innovations are contributing to scalability at each step.

Connect With Cell & Gene:
      Twitter